CYTK — Cytokinetics Income Statement
0.000.00%
Last trade - 00:00
- $6.57bn
- $6.17bn
- $7.53m
2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
Standards: | USG | USG | USG | USG | USG |
Status: | Final | Final | Final | Final | Final |
Revenue | |||||
Total Revenue | 26.9 | 55.8 | 70.4 | 94.6 | 7.53 |
Selling / General / Administrative Expenses | |||||
Research And Development | |||||
Unusual Expense / Income | |||||
Total Operating Expenses | 126 | 150 | 257 | 444 | 504 |
Operating Profit | -98.9 | -93.9 | -186 | -349 | -496 |
Total Net Non Operating Interest Income / Expense | |||||
Total Net Non Operating Interest Income / Expense | |||||
Net Income Before Taxes | -122 | -127 | -215 | -389 | -526 |
Provision for Income Taxes | |||||
Net Income After Taxes | -122 | -127 | -215 | -389 | -526 |
Net Income Before Extraordinary Items | |||||
Net Income | -122 | -127 | -215 | -389 | -526 |
Income Available to Common Shareholders Excluding Extraordinary Items | |||||
Income Available to Common Shareholders Including Extraordinary Items | |||||
Diluted Net Income | -122 | -127 | -215 | -389 | -526 |
Diluted Weighted Average Shares | |||||
Basic EPS Including Extraordinary Items | |||||
Diluted EPS Including Extraordinary Items | |||||
Diluted EPS Excluding Extraordinary Items | |||||
Normalised Income Before Taxes | |||||
Normalised Income After Taxes | |||||
Normalised Income Available to Common Shareholders | |||||
Diluted Normalised EPS | -2.11 | -1.97 | -2.76 | -4.05 | -5.45 |